IMPACT OF A TOOL IN THE ELECTRONIC CLINICAL HISTORY FOR THE OPTIMISATION OF BIOLOGIC DRUGS IN RHEUMATOLOGY (submitted in 2019)
4CPS-106
ANALYSIS OF THE PRESCRIPTION AND SAFE DRUG ADMINISTRATION OF OCRELIZUMAB (submitted in 2019)
4CPS-105
TOLERANCE PROFILE TO ANTI-THYMOCYTE IMMUNOGLOBULIN TREATMENT AND ITS RELATION TO INFECTIOUS PARAMETERS IN PAEDIATRIC PATIENTS (submitted in 2019)
4CPS-104
SWITCHING ORAL ANTIANDROGENIC TREATMENT IN PATIENTS WITH CASTRATE METASTATIC PROSTATE CANCER: AN ANALYSIS. (submitted in 2019)
4CPS-103
IS THERE A ROLE FOR THE PHARMACIST IN SCREENING FOR METABOLIC SYNDROME? (submitted in 2019)
4CPS-102
INFLUENCE OF PALBOCICLIB TOXICITY IN THE REAL WORLD CLINICAL PRACTICE (submitted in 2019)
4CPS-101
TRIFLURIDINE-TIPIRACIL FOR METASTATIC COLORECTAL CANCER: REAL WORLD DATA EXPERIENCE (submitted in 2019)
4CPS-100
ANTHRACYCLINE DOSING IN OBESE ADULT PATIENTS: A SYSTEMATIC REVIEW (submitted in 2019)
4CPS-099
REAL WORLD EVIDENCE OF PEMBROLIZUMAB AS MONOTHERAPY IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY STUDY (submitted in 2019)
4CPS-098
INDIRECT TREATMENT COMPARISONS OF IBRUTINIB-OBINOTUZUMAB VERSUS VENETOCLAX-OBINOTUZUMAB IN NAIVE CHRONIC LYMPHOCYTIC LEUKAEMIA (submitted in 2019)
4CPS-097
SECOND LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WITH IMMUNE CHECKPOINT INHIBITORS (submitted in 2019)
4CPS-096
EVALUATION OF CLINICAL PHARMACY SERVICES IN A HAEMATOLOGY OUTPATIENT SETTING. (submitted in 2019)
4CPS-095
REVIEWING THE LATEST CLINICAL RESEARCH FOR TREATING ADVANCED NON-SMALL CELL LUNG CANCER: SELECTION OF RANDOMISED CONTROLLED TRIALS PUBLISHED IN 2018 (submitted in 2019)
4CPS-094
CHARACTERISATION OF POTENTIAL DRUG-DRUG INTERACTIONS IN ONCOLOGICAL PATIENTS TREATED WITH ORAL ANTICANCER DRUGS (submitted in 2019)
4CPS-093
EFFECTIVENESS OF DEXAMETHASONE MOUTHWASH 0.1MG/ML FOR PREVENTION OF EVEROLIMUS RELATED STOMATITIS (submitted in 2019)
